Hotta, Azumi
Iwatani, Hirotsugu
Article History
Received: 12 March 2023
Accepted: 10 August 2023
First Online: 14 September 2023
Declarations
:
: The institutional review board (IRB) of the National Hospital Organization Osaka National Hospital approved this study (name of the IRB: National Hospital Organization Osaka National Hospital IRB #2; IRB number 19121). This study was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki). Owing to the retrospective nature of the study, the study was conducted with an opt-out policy as mentioned on the hospital webpage, and the need for written informed consent was waived by the National Hospital Organization Osaka National Hospital IRB #2. The eligible participants could withdraw from the study at any time through the opt-out procedure.
: Not applicable.
: AH declares that she has no competing interests. HI received grant support from Otsuka and lecture fees from Mochida, Kyowa Kirin, Otsuka, Mitsubishi Tanabe, Astellas Pharma, Boehringer Ingelheim, AstraZeneca and Bayer. He received research cost from AstraZeneca and Bayer for participating in clinical trials led by the two companies.